Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

"The tumor marker" will be defined as "substances the concentration of which increases (or rarely decreases) in blood or urine by malignancy". These substances are not necessarily be tumor specific but can be normal constituents. There are so many substances which are called as tumor marker that to describe all of them in this article is impossible. Therefore, the description is limited in items such as: i) primary structure of CEA, ii) changes of serum AFP levels by development of experimental hepatoma in rats, iii) clinical diagnosis of liver cirrhosis and hepatoma by characterization of AFP, iv) oncogene products as the tumor marker. All other tumor markers which are currently available or will appear in the near future are listed up in tables with their names only.
 ...
PMID:[Present status of tumor markers]. 248 6

In order to study the clinical significance of IAP and ASP, we have measured serum concentration of IAP and ASP in patients with different cancer types including digestive organs, head and neck. Significantly higher correlation (coefficient of correlation = 0.924) was found between IAP and ASP. IAP and ASP levels were elevated in about 60-80% of cancer from digestive organs except hepatocellular carcinoma, and in about 56-100% of head and neck tumor. There was no correlation between IAP, ASP and various tumor markers (CEA, CA19-9, AFP) in all malignancies except pancreatic cancer. There was positive correlation between CEA and IAP, ASP in pancreatic cancer. IAP and ASP levels were significantly higher in patients with cancer having evidence of disease than the patients with cancer who had no evidence of disease, and so the determination of IAP and ASP was clinically useful for the diagnosis of tumor existence. At the time of diagnosis of recurrence, the levels of IAP and ASP were elevated in about 70% of patients with cancer recurrence. There was a definite relation between IAP, ASP and the gastric cancer stage. In later state (stage III and IV), serum IAP and ASP levels were significantly higher than the levels of stage I and II. In hepatocellular carcinoma without liver cirrhosis, the levels of IAP and ASP were higher than the patients with cirrhosis. The determination of IAP and ASP seems to be useful for monitoring clinical course, judgement of therapeutic effects.
 ...
PMID:[Clinical evaluation of serum immunosuppressive acidic protein (IAP) and acid soluble glycoproteins (ASP) in patients with malignant tumors]. 248 24

Serum levels of SPan-1 were determined in patients with various gastrointestinal cancers including pancreatic cancer and benign disorders, as well as from healthy subjects, by using a newly developed SPan-1 antigen immunoradiometric assay (SPan-1 RIABEAD, Dainabott). In addition, usefulness of diagnosis for pancreatic cancer by determination of Serum SPan-1 antigen was compared with that of other tumor markers such as CA 19-9, DU-PAN 2, CA 50, CEA and elastase 1 in the same patients. Serum SPan-1 antigen levels in healthy controls ranged from 0 to 156 U/ml with a mean of 7.7 U/ml (+/- 15.0, 2 S.D). Thirty U/ml of serum SPan-1 antigen levels was set as the cut-off value, and 98.9% of healthy controls were within this cut-off value (30 U/ml). Serum SPan-1 antigen levels in pancreatic cancer were distributed from 0-353, 900 U/ml with a mean of 14,466 U/ml (+/- 16.616 SD). Sensitivity of SPan-1 antigen in pancreatic cancer was 81.9%, which was the highest among gastrointestinal cancers, and eight of nine pancreatic cancer patients with stage II showed above normal limits (30 U/ml). Although serum SPan-1 antigen levels in biliary tract cancer and liver cirrhosis showed a high percentage (70.3%, 56.8%), the mean values of SPan-1 antigen levels in these groups were 477 U/ml and 62.8 U/ml, respectively, which was lower than that of pancreatic cancer. False positive ratio of SPan-1 antigen in benign pancreatic disease was lower than that of CA 19-9. Also, comparative studies of SPan-1 antigen and various tumor markers between pancreatic cancer and benign gastrointestinal diseases revealed that SPan-1 antigen showed the highest sensitivity and accuracy in diagnosis for pancreatic cancer among other tumor markers. From these results, measurement of SPan-1 antigen appeared to be the most useful marker in the diagnosis of pancreatic cancer.
 ...
PMID:[Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. 273 18

In order to verify the role of CEA in the differential diagnosis of pancreatic cancer and to evaluate some influencing factors like age, tumor spread and liver dysfunction, this antigen was measured in the sera of 60 control subjects, 45 patients with pancreatic cancer, 37 with chronic pancreatitis, 67 with benign, and 28 with malignant extra-pancreatic diseases. CEA was found to be elevated in 23/45 pancreatic cancers, in 8/37 chronic pancreatitis, in 17/67 benign and in 9/28 malignant extra-pancreatic diseases. Significant correlations were documented between CEA and age in all the subjects; between CEA and immunoglobulins G in liver cirrhosis and between CEA and alkaline phosphatase in gastrointestinal extra-pancreatic malignancies. In pancreatic cancer higher CEA levels were detected in patients with metastases. We can conclude that CEA is of limited value in the differential diagnosis of pancreatic cancer; it does not seem to be able to detect early pancreatic tumors. Age and liver dysfunction may contribute towards elevating this marker in serum.
 ...
PMID:Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumour spread, liver impairment, and age. 316

In this paper the clinical usefulness of CEA and ferritin in the diagnosis of pancreatic cancer was pointed out. CEA was found to be increased in 51% of patients with pancreatic cancer; it was also abnormal in 22% of chronic pancreatitis and 31% of extra-pancreatic diseases. In patients with metastatic pancreatic cancer CEA was found to be more elevated than in those with localized tumor. CEA correlated with the age of the subjects in all material; in liver cirrhosis with IgG and in extra-pancreatic gastro-intestinal malignancies with alkaline-phosphatase. Ferritin was found to be increased in 73% of pancreatic cancer patients; it was also abnormal in 40% of chronic pancreatitis and in 38% of extra-pancreatic diseases. Patients with chronic pancreatitis studied during a relapsing phase all had elevated serum ferritin. We can conclude that neither CEA nor ferritin are useful indices of pancreatic malignancy, due to the lack of sensitivity or specificity. Both are influenced by several factors: CEA mainly by age and liver dysfunction, ferritin by the presence of an acute inflammation with cell necrosis.
 ...
PMID:Limits of CEA and ferritin in the diagnosis of pancreatic cancer. 320 64

Serum levels of CA15-3, a mammary tumor associated antigen recognized by two different murine monoclonal antibodies (115D8 and DF3), were investigated in patients with mammary carcinoma and other benign or malignant diseases. The reference value of the serum CA15-3 level was obtained as 24 units/ml at the 99% confidence limit among healthy individuals (n = 462). Elevation of serum CA15-3 levels was observed in 24.3% of overall patients with mammary carcinoma. Serum CA15-3 levels in breast cancer patients correlated with the clinical stage; higher percentages of positivity were observed in those with advanced breast cancer (stage IV, 64.7%, recurrent, 52.4% and metastatic, 70.3%). Furthermore, elevated serum CA15-3 levels in breast cancer patients responded well to the effect of therapy. Although the serum CA15-3 test gave percentages of positivity of breast cancer similar to those found by the serum CEA test, the serum CA15-3 test revealed lower percentages of positivity than the serum CEA test among patients with benign breast lesions, liver cirrhosis or other carcinomas. These results suggest that the serum CA15-3 antigen level provides a very useful marker for diagnosis and clinical monitoring of patients with breast cancer.
 ...
PMID:Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. 346 6

In order to assess the diagnostic value of CA-50, a new tumour marker, a series of 226 patients with gastroenteric tumours, 152 healthy controls and 175 patients with benign gastrointestinal pathologies, was examined. CEA, CA 19-9, Alphafetoprotein and CA-50 were assayed in all subjects and the results subjected to statistical analysis in order to discover the sensitivity, specificity and diagnostic value of the new marker. Studies conducted to date indicate that CA-50 assays may be of some value in the diagnosis of pancreatic and liver tumours but are no improvement on existing markers in clinical use, for the diagnosis of gastroenteric tumours. Indeed CA-50 gives a very large number of false positive especially in cirrhosis and to a lesser extent in chronic pancreatitis.
 ...
PMID:[CA-50: evaluation of a new tumor marker in the diagnosis of neoplastic pathologies of the gastrointestinal tract]. 346 41

In order to evaluate the usefulness of serum DU-PAN-2, we determined this antigen in 384 patients with various malignancies and in 215 patients with benign diseases using a sandwich enzyme immunoassay system (Kyowa Medex Co.). Elevated DU-PAN-2 levels (greater than 400 U/ml) were observed in 55% of hepatocellular cancers, 50% of pancreatic cancers, and 43% of biliary tract cancers. On the other hand, most false-positive cases with benign diseases were observed in patients with liver injury, especially in the acute phase of acute hepatitis, chronic active hepatitis, and liver cirrhosis. However, in only a few cases with other benign diseases including pancreatitis, increased levels were found. Moreover, among the pancreatic cancer or biliary tract cancer patients studied, DU-PAN-2 was positive in 7 of the 19 CA 19-9-negative (less than 37 U/ml) patients and 32 of the 68 CEA-negative (less than 5 ng/ml) patients. These results indicate that the assay of DU-PAN-2 by EIA may have diagnostic usefulness in digestive cancer, especially pancreatic cancer or biliary tract cancer.
 ...
PMID:[Determination of serum DU-PAN-2 by enzyme immunoassay in patients with various digestive cancers]. 354 91

The serum levels of alpha-1-antichymotrypsin (ACT) were studied in 168 patients with various liver diseases and cancers in conjunction with other liver function tests, serum sialic acid, AFP and CEA. The ACT levels in acute viral hepatitis and chronic hepatitis were not significantly altered compared with the normal level (220 +/- 40 microgram/ml), although the level was slightly increased or decreased temporarily during the acute phase of the former. In liver cirrhosis, the mean level was significantly lower than the normal in spite of the absence of signs of hepatic decompensation (168 +/- 51 microgram/ml, p less than 0.001). In contrast to cirrhosis, the levels were increased to various extents in 65% of cases with hepatoma, in spite of the association of liver cirrhosis in the majority of them. Much higher levels were observed in all cases of metastatic liver cancers and cancers of the pancreas and the biliary tract. The elevations were observed even in cases without the increase of AFP or CEA. Both in cirrhosis and cancers, ACT levels were not correlated with any of serum bilirubin and serum enzyme activities, but were positively correlated with the levels of plasma fibrinogen and serum sialic acid. The measurement of serum ACT level can be taken advantage of for the diagnosis and monitoring of liver cirrhosis and liver cancers, particularly of hepatoma without AFP elevation.
 ...
PMID:A clinical evaluation of serum alpha-1-antichymotrypsin levels in liver disease and cancers. 617 85

Immunological analysis of ascitic fluids from 49 patients with gastrointestinal cancer was performed and compared to those from 13 patients with hepatic cirrhosis and 3 with congestive heart failure. The analysis of ascitic fluid was performed using natural killer (NK) activity, MLR, PHA-induced lymphoproliferation (LP) and PPD-LP. Immunologic suppression by malignant ascitic fluid was more remarkably observed in PHA-LP, PPD-LP, MLR and NK assay than that by cirrhotic ascites, and it was further proved to be dose dependent. Ascitic fluids from patients with congestive heart failure showed no suppressive effects. There was no correlation between these suppressions and AFP, CEA or immunosuppressive acidic protein (IAP) levels in ascitic fluids. The first fraction of sephadex G 200 Gel filtration, which has a molecular weight of more than 200,000, showed the immunosuppressive activity. It is concluded from these results that this immunosuppressive factor does not involve AFP, CEA and IAP. Thus, it is presumed that the prognosis of the patients with gastrointestinal cancer might correlate with the immunosuppressive factor in their ascitic fluid.
 ...
PMID:[Suppression of immunological response by ascitic fluid from gastrointestinal cancer patients]. 620 9


<< Previous 1 2 3 4 Next >>